References
1. Sopfe J, Endres A, Campbell K, et al. Castleman disease in pediatrics: Insights on presentation, treatment, and outcomes from a two-site retrospective cohort study. Pediatr Blood Cancer 2019;66:e27613.
2. Dispenzieri A, Fajgenbaum DC. Overview of Castleman disease. Blood 2020;135:1353-1364.
3. Biggs CM, Keles S, Chatila TA. DOCK8 deficiency: Insights into pathophysiology, clinical features and management. Clin Immunol 2017;181:75-82.
4. Aydin SE, Kilic SS, Aytekin C, et al. DOCK8 deficiency: clinical and immunological phenotype and treatment options - a review of 136 patients. J Clin Immunol 2015;35:189-198.
5. Engelhardt KR, Gertz M, Keles S, et al. The extended clinical phenotype of 64 patients with dedicator of cytokinesis 8 deficiency. J Allergy Clin Immunol 2015;136:402-412.
6. Bergqvist C, Kurban M, Abbas O. Orf virus infection. Rev Med Virol 2017;27:4.
7. Liu AY, Nabel C, Finkelman BS, et al. Idiopathic multicentric Castleman’s disease: a systematic literature review. Lancet Haematol 2016;3:163-175.
8. Drolet JP, Lefebvre MA, Bernard C, et al. Multicentric castleman disease in a child with primary immunodeficiency. Pediatr Blood Cancer 2010:55:1198-1200.
9. Guihot A, Oksenhendler E, Galicier L, et al. Multicentric Castleman disease is associated with polyfunctional effector memory HHV-8–specific CD8+ T cells. Blood 2008;111:1387–1395.
10. Leroy S, Moshous D, Cassar O, et al. Multicentric Castleman disease in an HHV8-infected child born to consanguineous parents with systematic review. Pediatrics 2012;129:199-203.
11. Wilkinson JD. Orf: a family with unusual complications. Br J Dermatol. 1997;97:447-450.
12. Kilic SS, Puel A, Casanova JL. Orf Infection in a Patient with Stat1 Gain-of-Function. Journal of Clinical Immunology 2015;35:80-83.
13. Ozkaya DB, Taskın B, Tas B, et al. Poxvirus-induced angiogenesis after a thermal burn. Journal of Dermatology 2014;41:830-833.
14. Wise LM, Inder MK, Stuart GS, et al. The vascular endothelial growth factor (VEGF)‐E encoded by orf virus regulates keratinocyte proliferation and migration and promotes epidermal regeneration. Cellular Microbiology 2012;14:1376-1390.
15. Midilli K, Erkilic A, Kuskucu M, et al. Nosocomial outbreak of disseminated orf infection in a burn unit, Gaziantep, Turkey, October to December 2012. Eurosurveillance 2013;18:20425.
16. Imahorn E, Yüksel Z, Spoerri I, et al. Novel TMC8 splice site mutation in epidermodysplasia verruciformis and review of HPV infections in patients with the disease. J Eur Acad Dermatol Venereol. 2017;31:1722.
17. Burger B, Itin PH. Epidermodysplasia verruciformis. Curr Probl Dermatol 2014;45:123.
18. Nishimoto N, Kanakura Y, Aozasa K, et al. Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood 2015:106:2627-2632.
19. Rieu P, Noël LH, Droz D, et al. Glomerular involvement in lymphoproliferative disorders with hyperproduction of cytokines (Castleman-POEMS). Adv Nephrol Necker Hosp 2000;30:305-331.
20. Nabel CS, Sameroff S, Shilling D, et al. Viroma capture sequencing does not identify active viral infection in unicentric and idiopathic multicentric Castleman disease. PLoS One 2019;14(6):e0218660.
Table-1 . Complete blood count and biochemical features of patient